TransCode Therapeutics Inc. (RNAZ): O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati
TransCode Therapeutics (RNAZ) RNA-ga asoslangan saratonga qarshi dori vositalarini ishlab chiqish uchun yetakchi genetiklarni birlashtiradi. Past baholangan o'sish kompaniyalari skrineri aktivning qiymat dinamikasini vizuallashtiradi, bunda 0.00 joriy metrika hajmini ko'rsatadi. Yuqori daromadlilik innovatsion molekulalarga bo'lgan barqaror klinika talabi bilan ta'minlanadi, garchi yakuniy kapitalizatsiya metastaz terapiyasi uchun nanoparticleslarning klinik sinov natijalariga bog'liq bo'lsa-da.
TransCode Therapeutics (RNAZ) kompaniyasining tahliliy kesimlari
- aksiya narxi va konsensus maqsadli narx:
- birja kapitallashuvi ma'lumotlari:
- kompaniyaning balans qiymati tafsilotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning xususiy kapitalga nisbati TransCode Therapeutics|RNAZ - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati transcodetherapeutics.com|RNAZ - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati TransCode|RNAZ - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori TransCode Therapeutics|Oraliq qoplash koeffitsiyenti transcodetherapeutics.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
RNAZ - Sof foyda|Kutilayotgan sof foyda TransCode Therapeutics|RNAZ - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori transcodetherapeutics.com|RNAZ - PEG multiplikatori|EV/EBITDA multiplikatori TransCode|RNAZ - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi 12 oy davomida bitta aksiya uchun foyda TransCode Therapeutics|RNAZ - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi transcodetherapeutics.com|RNAZ - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi TransCode Therapeutics
Kompaniyaning jamlanma tahliliyoti:TransCode Therapeutics Inc., RNAZ
Ushbu ko'rsatkich aktivning bozor qiymati uning dinamikasiga nisbatan adolatli ekanligini aniqlash uchun joriy P/E ko'paytirgichini sof foyda o'sish sur'ati bilan solishtiradi. Birga solishtirganda pastroq qiymat aktivning qadrsizlanganligidan dalolat beradi, bu esa TransCode Therapeutics (RNAZ) o'zining RNA dori yetkazib berish platformasini kengaytirayotgan davrda juda muhimdir va PEG ko'rsatkichi onkologiya bozoriga kirish samaradorligini baholash imkonini beradi.
TransCode Therapeutics kimlar bilan raqobatlashadi
Tempus AI, Inc - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Qiagen Group QGEN|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Isis Pharmaceuticals (IONS)|Repligen Corporation - PEG multiplikatori|aviditybiosciences.com (RNA) - Narx-foyda va o‘sish multiplikatori|CRISPR Therapeutics (CRSP) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atiga tuzatilgan narx-foyda GeneDx Holdings (WGS)|RARE (Ultragenyx Pharma) - PEG multiplikatori|O‘sishni hisobga olgan narx-foyda koeffitsiyenti BEAM (Beam Tx)|PEG multiplikatori SRPT|TWST - O‘sish sur’atiga tuzatilgan narx-foyda|10x Genomics - Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti NTLA|STOK: Narx-foyda va o‘sish multiplikatori|BioLife - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|WVE: PEG multiplikatori|mazetx.com - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|SION (Sionna Therapeutics) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Prime Medicine Inc PRME|Narxning foydaga va o‘sish sur’atiga nisbati Taysha (TSHA)|QURE (uniQure Pharma) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori MGTX (MeiraGTx Holdings plc)|PEG multiplikatori regenxbio.com RGNX|SLDB - Narxning foydaga va o‘sish sur’atiga nisbati|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati OCGN|PACB: PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Benitec Corp (BNTC)|Narx-foyda va o‘sish multiplikatori DSGN|PEG multiplikatori rocketpharma.com|Narx-foyda va o‘sish multiplikatori FDMT (4D Molecular Therapeutics, Inc.)|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati LXEO|PEG multiplikatori KRRO (Korro Bio)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Editas Corp (EDIT)|Silence Therapeutics - PEG multiplikatori|ProQR Therapeutics N.V. (PRQR) - Narx-foyda va o‘sish multiplikatori|codexis.com (CDXS) - Narxning foydaga va o‘sish sur’atiga nisbati|SGMO - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Nautilus Biotechnology, Inc.|MGX: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati Precision BioSciences (DTIL)|generationbio.com - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|PEG multiplikatori BOLD (Boundless Bio)|PEG multiplikatori Exicure Inc. XCUR|IMNN: Narx-foyda va o‘sish multiplikatori|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati PHIO|MBIO: PEG multiplikatori|O‘sishni hisobga olgan narx-foyda koeffitsiyenti BNGO|Narxning foydaga va o‘sish sur’atiga nisbati Applied DNA Sciences, Inc.|O‘sishni hisobga olgan narx-foyda koeffitsiyenti BLUE (bluebird bio Inc.)|PEG multiplikatori IPA|PEG multiplikatori Omega Therapeutics Corp (OMGA)|Singular Genomics Systems - Narx-foyda va o‘sish multiplikatori|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati RGLS (regulusrx.com)|SYRS - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti TBIO (Telesis Bio Inc.)|TCON: PEG multiplikatori|Unity Biotechnology, Inc (UBX) - PEG multiplikatori
